Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial. (PubMed, Rheumatol Immunol Res) - Apr 13, 2026 - "No treatment-emergent anti-drug antibodies were detected. Xeligekimab at 100 mg and 200 mg achieved meaningful clinical improvement with good tolerability in patients with active axSpA, supporting further clinical evaluation of this therapy."
Clinical • Journal • P2 data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A
|
|
Dong Xu; Huaxiang Liu; Jiankang Hu; Lingyun Sun; Liying Shen; Ning Kong; Shangzhu Zhang; Shengyun Liu; Xiaofeng Zeng; Xiaomei Li; Xiaoyun Fan; Yi Zhao; Yu Xue; Zhenyu Jiang
|